Sonoma Pharmaceuticals (FRA:O8Z) Cyclically Adjusted Revenue per Share: €388.62 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:O8Z Sonoma Pharmaceuticals Inc FRA:O8Z
34 GF Score
Price €2.72
GF Value €6.17
! 4 Warning Signs
View Full Analysis

What is Sonoma Pharmaceuticals Cyclically Adjusted Revenue per Share?

Sonoma Pharmaceuticals FRA:O8Z 34 Cyclically Adjusted Revenue per Share is €388.62 as of Mar. 2026. GuruFocus rates FRA:O8Z with a GF Score™ of 34/100 and a GF Value™ of €6.17. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Sonoma Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2026 was €2.772. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €388.62 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Sonoma Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was -21.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -26.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -26.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -18.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Sonoma Pharmaceuticals was -3.00% per year. The lowest was -28.90% per year. And the median was -12.95% per year.

As of today (2026-08-06), Sonoma Pharmaceuticals's current stock price is €2.72. Sonoma Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €388.62. Sonoma Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 0.01.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sonoma Pharmaceuticals was 0.70. The lowest was 0.01. And the median was 0.07.


Sonoma Pharmaceuticals  (FRA:O8Z) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sonoma Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2.72/388.62
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sonoma Pharmaceuticals was 0.70. The lowest was 0.01. And the median was 0.07.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Sonoma Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Sonoma Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Sonoma Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sonoma Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Sonoma Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 863.21 756.60 470.87 482.89 388.62

Sonoma Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 482.89 347.19 235.03 236.02 388.62

FRA:O8Z vs YCBD, CVSI, AKAN: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sonoma Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sonoma Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


FRA:O8Z
34GF Score
Sonoma Pharmaceuticals Inc FRA:O8Z
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sonoma Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sonoma Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.772/330.2130*330.2130
=2.772

Current CPI (Mar. 2026) = 330.2130.

Sonoma Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 102.087 241.018 139.867
201609 108.391 241.428 148.252
201612 138.522 241.432 189.460
201703 156.958 243.801 212.590
201706 142.208 244.955 191.704
201709 151.208 246.819 202.297
201712 170.500 246.524 228.381
201803 105.857 249.554 140.071
201806 106.857 251.989 140.028
201809 117.583 252.439 153.809
201812 94.714 251.233 124.489
201903 58.758 254.202 76.328
201906 59.373 256.143 76.542
201909 65.030 256.759 83.634
201912 52.747 256.974 67.780
202003 43.843 258.115 56.089
202006 55.663 257.797 71.299
202009 45.352 260.280 57.537
202012 39.388 260.474 49.934
202103 17.423 264.877 21.721
202106 29.124 271.696 35.397
202109 27.197 274.310 32.740
202112 16.675 278.802 19.750
202203 13.465 287.504 15.465
202206 24.310 296.311 27.091
202209 21.703 296.808 24.146
202212 17.929 296.797 19.948
202303 13.216 301.836 14.458
202306 12.806 305.109 13.860
202309 9.919 307.789 10.642
202312 5.271 306.746 5.674
202403 4.056 312.332 4.288
202406 3.702 314.175 3.891
202409 3.119 315.301 3.267
202412 2.325 315.605 2.433
202503 2.153 319.799 2.223
202506 2.121 322.561 2.171
202509 2.901 324.800 2.949
202512 2.168 324.054 2.209
202603 2.772 330.213 2.772

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €388.62 mean?
Sonoma Pharmaceuticals (FRA:O8Z) has a Cyclically Adjusted Revenue per Share of €388.62 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sonoma Pharmaceuticals and its competitors.
Is Sonoma Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Sonoma Pharmaceuticals' current Cyclically Adjusted Revenue per Share is €388.62. Overall, Sonoma Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Sonoma Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to YCBD and CVSI?
Sonoma Pharmaceuticals' Cyclically Adjusted Revenue per Share of €388.62 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sonoma Pharmaceuticals and its competitors. Sonoma Pharmaceuticals's current Cyclically Adjusted Revenue per Share is €388.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonoma Pharmaceuticals stock overvalued right now?
Sonoma Pharmaceuticals (FRA:O8Z) has a current Cyclically Adjusted Revenue per Share of €388.62. The stock's GF Value™ is €6.17, compared to a current price of €2.72 — trading 55.9% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €388.62. Sonoma Pharmaceuticals' overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Sonoma Pharmaceuticals (FRA:O8Z), the current Cyclically Adjusted Revenue per Share is €388.62 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sonoma Pharmaceuticals (FRA:O8Z) Overvalued in 2026?

Based on GuruFocus' analysis, Sonoma Pharmaceuticals stock appears to be undervalued. The current stock price of €2.72 is trading 55.9% below its estimated GF Value™ of €6.17.

Key valuation signals for FRA:O8Z:

  • Cyclically Adjusted Revenue per Share: €388.62
  • GF Value™: €6.17 vs. price of €2.72 (55.9% below fair value)
  • GF Score™: 34/100 with 4 warning signs

No single metric tells the full story. See the FRA:O8Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sonoma Pharmaceuticals Business Description

Other Exchanges SNOA:USA
Address 5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
34GF Score

Get the complete analysis for FRA:O8Z

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.72
Price
€6.17
GF Value